Status:
COMPLETED
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Lead Sponsor:
Celgene
Conditions:
Advanced Solid Tumors
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the invest...
Eligibility Criteria
Inclusion
- Other specific eligibility criteria may apply. Examination by the investigator is necessary to fully determine eligibility.
- Ability and willingness to provide written informed consent
- Histologically or cytologically confirmed solid tumors or lymphoma
- Locally advanced or metastatic disease
- Life expectancy of at least 16 weeks
- ECOG performance status of 0 or 1
- Acceptable physical exam and laboratory tests at study entry
- Willingness to use medically acceptable contraception
- A negative serum pregnancy test for women with reproductive potential
Exclusion
- Anticancer therapy within 2 weeks
- Treatment with an investigational agent within 4 weeks
- Systemic corticosteroids within 2 weeks or a requirement for systemic immunosuppressive therapy
- Known brain metastases unless stable for at least 28 days
- Active autoimmune disease
- Insulin-dependent diabetes mellitus
- Clinically significant cardiac disease within 6 months
- Significant infection or fever within 1 week
- Pregnant or breast-feeding females
- Other conditions or circumstances that could interfere with the study
Key Trial Info
Start Date :
November 7 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00688415
Start Date
November 7 2008
End Date
November 1 2010
Last Update
September 25 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Scottsdale, Arizona, United States
2
Scottsdale Healthcare
Scottsdale, Arizona, United States